CHU Brest

The medical center is at the forefront of oncology research, focusing on innovative treatments for advanced prostate cancer. The center's work in this field is pivotal in developing new therapeutic strategies that aim to improve patient outcomes and quality of life.

• Metastatic Castration-Resistant Prostate Cancer
• Combination Therapies
• Anti-androgen Treatments

By exploring the efficacy of novel drug combinations, the center contributes significantly to the understanding and management of complex cancer cases.

Specializing in pharmacology, the center is dedicated to identifying the safety and tolerability of new drug regimens. This research is crucial for establishing effective dosage guidelines and minimizing adverse effects in patients undergoing treatment.

• Safety and Tolerability Studies
• Maximum Tolerated Dose Identification
• Dose Limiting Toxicities

The center's efforts in pharmacological research ensure that new therapies are both safe and effective, paving the way for their integration into clinical practice.

The institution is renowned for its comprehensive clinical trials program, which evaluates the anti-tumor activity of emerging treatments. These trials are essential for translating laboratory findings into real-world medical applications.

• Phase 1 and Phase 2 Trials
• Comparative Efficacy Studies
• Patient Safety Monitoring

Through rigorous clinical trials, the center plays a critical role in advancing medical knowledge and offering new hope to patients with challenging conditions.